USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: Feasibility and biodistribution study

Journal of Magnetic Resonance Imaging

Volumn 28, Issue 4, 2008, Pages 1046-1052

  Azoulay, Robin ^a,b   Olivier, Paul ^a   Baud, Olivier ^a,b   Verney, Catherine ^b   Santus, Robin ^c   Robert, Philippe ^c   Gressens, Pierre ^a   Sebag, Guy ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Laboratoire Guerbet   (France)

Author keywords

Ferumoxtran 10; Magnetic resonance imaging; Newborn; Reticuloendothelial system; USPIO

Indexed keywords

FERUMOXTRAN 10; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MEGADOSE; ENDOTHELIUM CELL; FEASIBILITY STUDY; IRON BLOOD LEVEL; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION;

ANIMALS; ANIMALS, NEWBORN; BONE MARROW; CONTRAST MEDIA; FEASIBILITY STUDIES; IRON; MAGNETIC RESONANCE IMAGING; MONONUCLEAR PHAGOCYTE SYSTEM; OXIDES; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; STATISTICS, NONPARAMETRIC; TISSUE DISTRIBUTION;

EID: 53549094674     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21510     Document Type: Article

References (35)

1. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494-498.
2. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006;7:52-60.
3. Sigal R, Vogl T, Casselman J, et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) - results of a phase-III multicenter clinical trial. Eur Radiol 2002;12:1104-1113.
4. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004;39:619-625.
5. Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999;20:223-227.
6. Dousset V, Delalande C, Ballarino L, et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999;41:329-333.
7. Dousset V, Gomez C, Petry KG, Delalande C, Caille JM. Dose and scanning delay using USPIO for central nervous system macrophage imaging. MAGMA 1999;8:185-189.
8. Floris S, Blezer EL, Schreibelt G, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004;127:616-627.
9. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003;50:309-314.
10. Rausch M, Sauter A, Frohlich J, Neubacher U, Radu EW, Rudin M. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn Reson Med 2001;46:1018-1022.
11. Rausch M, Baumann D, Neubacher U, Rudin M. In-vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed 2002;15:278-283.
12. Saleh A, Wiedermann D, Schroeter M, Jonkmanns C, Jander S, Hoehn M. Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging. NMR Biomed 2004;17:163-169.
13. Wiart M, Davoust N, Pialat JB, et al. MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke 2007;38:131-137.
14. Petry KG, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 2007;4:434-442.
15. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004;127:1670-1677.
16. Nighoghossian N, Wiart M, Cakmak S, et al. Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in patients. Stroke 2007;38:303-307.
17. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006;27:1000-1005.
18. Chambon C, Clement O, Le Blanche A, Schouman-Claeys E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993;11:509-519.
19. Harisinghani MG, Saini S, Weissleder R, et al. Splenic imaging with ultrasmall superparamagnetic Iron oxide ferumoxtran-10 (AMI-7227): preliminary observations. J Comput Assist Tomogr 2001;25:770-776.
20. Daldrup HE, Link TM, Blasius S, et al. Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI. J Magn Reson Imaging 1999;9:643-652.
21. Seneterre E, Weissleder R, Jaramillo D, et al. Bone marrow: ultrasmail superparamagnetic iron oxide for MR imaging. Radiology 1991;179:529-533.
22. Tahraoui SL, Marret S, Bodenant C, et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol 2001;11:56-71.
23. Baud O, Daire JL, Dalmaz Y, et al. Gestational hypoxia induces white matter damage in neonatal rats: a new model of periventricular leukomalacia. Brain Pathol 2004;14:1-10.
24. Olivier P, Baud O, Evrard P, Gressens P, Verney C. Prenatal ischemia and white matter damage in rats. J Neuropathol Exp Neurol 2005;64:998-1006.
25. Bourasset F, Dencausse A, Bourrinet P, Ducret M, Corot C. Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. Magma 2001;12:82-87.
26. Hilfiker PR, Debatin JF, Tarlo K, Schmitz HC, Kurrer MO. Assessment of peritoneal tolerance of a new MR blood pool contrast agent in rabbits. Invest Radiol 1999;34:722-727.
27. Reddy DK, Moore HL, Lee JH, et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int 2001;59:764-773.
28. Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 1996;16:646-648.
29. Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes od administration. Magn Reson Imaging 1994;12:433-442.
30. Nakayama A, Bianco AC, Zhang CY, Lowell BB, Frangioni JV. Quantitation of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol Imaging 2003;2:37-49.
31. Briley-Saebo K, Hustvedt SO, Haldorsen A, Bjornerud A. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent. J Magn Reson Imaging 2004;20:622-631.
32. Simon GH, Raatschen HJ, Wendland MF, et al. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research. Acad Radiol 2005;12:1190-1197.
33. Daldrup-Link HE, Rummeny EJ, Ihssen B, Kienast J, Link TM. Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol 2002;12:1557-1566.
34. Sharma R, Saini S, Ros PR, et al. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J Magn Reson Imaging 1999;9:291-294.
35. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301-307.